PNS75 COMPARISON OF US ICER'S COST-EFFECTIVENESS THRESHOLD PRICE WITH COST PAID BY US PAYERS AND PUBLIC PAYERS IN OTHER HTA COUNTRIES
نویسندگان
چکیده
منابع مشابه
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
OBJECTIVES Public programs finance a large share of the US pharmaceutical expenditures. To date, there are not guidelines for estimating the cost of drugs financed by US public programs. The objective of this study was to provide standards for estimating the cost of drugs financed by US public programs for utilization in pharmacoeconomic evaluations. METHODS This report was prepared by the IS...
متن کاملCost-effectiveness decision making and US public opinion.
HEALTHCAREREFORM Cost-Effectiveness DecisionMaking andUS Public Opinion As nations seek to stem the tide of rising health care spending, many have turned to cost-effectiveness research (CER) as a way to reduce spending on low-value interventions. Agencies in the United Kingdom, Italy, Germany, and Australia judge the clinical benefits and costs of new treatments relative to the current standard...
متن کاملSpecialty pharmacy cost management strategies of private health care payers.
BACKGROUND The rate of increase in spending on specialty pharmaceuticals is outpacing by far the rate of increase in spending for other drugs. OBJECTIVE To explore the strategies payers are using in response to challenges related to coverage, cost, clinical management, and access of specialty pharmaceuticals and to describe the potential implications for key stakeholders, including patients, ...
متن کاملCost effectiveness of pramipexole in Parkinson's disease in the US.
OBJECTIVE Pramipexole was recently approved in the US for treatment of the symptoms of idiopathic Parkinson's disease (PD). Although pramipexole has been found to be safe and efficacious when compared with placebo, little data are yet available on its cost effectiveness when compared with baseline treatment. The aim of this study was to estimate the costs and cost effectiveness (cost utility) o...
متن کاملPrior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
BACKGROUND Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an innovative treatment option for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require further lowering of low-density lipoprotein cholesterol. However, the high costs of these agents have spurred payers to implement utilization management policies to ensure a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2020
ISSN: 1098-3015
DOI: 10.1016/j.jval.2020.04.1078